

### STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 WYOMING

#### LIST OF TABLES

#### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

#### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

#### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

#### FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC

TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

#### SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY  $^{a,\ b}$ NONDUAL BENEFICIARIES, WYOMING, 2005

			Number of	Beneficia	aries			N	umber of B	enefit Mo	onths	
Beneficiary Characteristics	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	70,687	73	5,067	12,994	52,401	152	629,372	509	52,125	94,615	480,833	1,290
Age												
5 and younger	22,162	0	293	0	21,869	0	207,058	0	3,002	0	204,056	0
6-14	20,565	0	748	0	19,817	0	197,736	0	8,245	0	189,491	0
15-20	10,743	0	622	716	9,401	4	93,856	0	6,658	4,794	82,377	27
21-44	13,223	0	1,683	11,422	38	80	100,977	0	17,164	82,898	258	657
45-64	2,641	0	1,718	855	0	68	24,579	0	17,052	6,921	0	606
65-74	27	24	3	0	0	0	232	228	4	0	0	0
75-84	22	22	0	0	0	0	128	128	0	0	0	0
85 and older	26	26	0	0	0	0	152	152	0	0	0	0
Unknown	1,278	1	0	1	1,276	0	4,654	1	0	2	4,651	0
Gender												
Female	38,419	46	2,684	10,611	24,926	152	338,355	293	27,914	77,217	231,641	1,290
Male	30,467	27	2,383	2,383	25,674	0	283,319	216	24,211	17,398	241,494	0
Unknown	1,801	0	0	0	1,801	0	7,698	0	0	0	7,698	0
Race												
White	55,008	60	4,044	10,400	40,363	141	485,301	407	41,742	74,212	367,724	1,216
African American	1,380	0	122	175	1,083	0	12,427	0	1,178	1,239	10,010	0
Other/unknown	14,299	13	901	2,419	10,955	11	131,644	102	9,205	19,164	103,099	74
Use of Nursing Facilities <sup>c</sup>												
Entire year	85	18	67	0	0	0	757	143	614	0	0	0
Part year	93	4	88	1	0	0	789	42	735	12	0	0
None	70,509	51	4,912	12,993	52,401	152	627,826	324	50,776	94,603	480,833	1,290
Maintenance Assistance Statu	s											
Cash	16,437	23	3,831	5,876	6,707	0	148,574	214	39,788	44,265	64,307	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	37,274	0	0	3,520	33,602	152	335,838	0	0	20,738	313,810	1,290
Other/unknown	16,976	50	1,236	3,598	12,092	0	144,960	295	12,337	29,612	102,716	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	70,687	73	5,067	12,994	52,401	152	629,372	509	52,125	94,615	480,833	1,290
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

Characteristics         at Least One F           AII         61           Age         5 and younger         64           6-14         58           15-20         61           21-44         67           45-64         75           65-74         55	7 6.2  1 3.5  0 4.3  1 6.0  3 9.4  9 30.1  6 33.5	\$402 \$402 153 310 435 601 2,255 2,003	\$ per Rx \$65 44 72 73 64 75	\$3,491 2,475 2,051 3,590 5,832	FFS \$\frac{4}{5}\$  11.5  6.2  15.1  12.1	70,687  22,162 20,565
Age         5 and younger       64         6-14       58         15-20       61         21-44       67         45-64       75         65-74       55	1 3.5 0 4.3 1 6.0 3 9.4 9 30.1 6 33.5	153 310 435 601 2,255	44 72 73 64	2,475 2,051 3,590	6.2 15.1	22,162 20,565
5 and younger 64 6-14 58 15-20 61 21-44 67 45-64 75 65-74 55	0 4.3 1 6.0 3 9.4 9 30.1 6 33.5	310 435 601 2,255	72 73 64	2,051 3,590	15.1	20,565
6-14 58 15-20 61 21-44 67 45-64 75 65-74 55	0 4.3 1 6.0 3 9.4 9 30.1 6 33.5	310 435 601 2,255	72 73 64	2,051 3,590	15.1	20,565
15-20     61       21-44     67       45-64     75       65-74     55	1 6.0 3 9.4 9 30.1 6 33.5	435 601 2,255	73 64	3,590		
21-44 67 45-64 75 65-74 55	3 9.4 9 30.1 6 33.5	601 2,255	64		12.1	
45-64 75 65-74 55	9 30.1 6 33.5	2,255		5,832	10.0	10,743
65-74 55	6 33.5		/5	40.400	10.3	13,223
		2.003		12,466	18.1	2,641
	5 20/	,	60	16,651	12.0	27
75-84 45		756	37	10,154	7.4	22
85 and older 46		1,164	48	12,725	9.1	26
Unknown 0	2 0.0	1	119	100	1.4	1,278
Basis of Eligibilitye						
Aged 52		1,388	51	13,706	10.1	73
Disabled 78	3 26.6	2,356	89	18,422	12.8	5,067
Adults 66	2 7.5	382	51	3,493	10.9	12,994
Children 59	0 3.8	215	56	2,020	10.6	52,401
Unknown 62	5 13.6	1,067	79	7,897	13.5	152
Gender						
Female 65	8 7.1	428	60	3,661	11.7	38,419
Male 60	2 5.4	394	73	3,467	11.4	30,467
Unknown 1	1 0.0	2	90	267	0.7	1,801
Race						
White 64	2 6.7	442	66	3,601	12.3	55,008
African American 63	1 5.9	405	69	3,677	11.0	1,380
Other/unknown 52	2 4.1	251	62	3,050	8.2	14,299
Use of Nursing Facilities <sup>f</sup>						
Entire year 96	5 74.4	4,986	67	47,676	10.5	85
Part year 96	8 49.3	2,902	59	46,793	6.2	93
None 61	6.0	394	65	3,381	11.6	70,509
Maintenance Assistance Status						
Cash 64	1 10.9	778	72	4,680	16.6	16,437
Medically needy 0		0	0	0	0.0	0
Poverty related 61		201	52	1,650	12.2	37,274
Other/unknown 59	1 6.7	481	72	6,383	7.5	16,976

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving fost care and adoptive services. f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

						nber of Rx, F		rith:			Numbe	r
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>c</sup>	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less		Mean \$, All Medicaid FFS \$ <sup>d</sup>	Beneficiaries	Benefit Months
All	0.7	\$45	11.5	38.3	50.1	5.5	4.4	1.4	0.3	\$392	70,687	629,372
Age												
5 and younger	0.4	16	6.2	35.9	60.1	3.0	0.9	0.0	0.0	265	22,162	207,058
6-14	0.5	32	15.1	42.0	50.7	4.0	3.0	0.3	0.0	213	20,565	197,736
15-20	0.7	50	12.1	38.9	48.2	7.3	4.7	0.9	0.0	411	10,743	93,856
21-44	1.2	79	10.3	32.7	44.4	10.2	9.2	3.1	0.4	764	13,223	100,977
45-64	3.2	242	18.1	24.1	23.4	9.8	22.5	15.8	4.3	1,339	2,641	24,579
65-74	3.9	233	12.0	44.4	7.4	7.4	11.1	22.2	7.4	1,938	27	232
75-84	3.6	130	7.4	54.5	4.5	4.5	9.1	27.3	0.0	1,745	22	128
85 and older	4.1	199	9.1	53.8	7.7	0.0	11.5	23.1	3.8	2,177	26	152
Unknown	0.0	0	1.4	99.8	0.2	0.0	0.0	0.1	0.0	27	1,278	4,654
Basis of Eligibility	/e											
Aged	3.9	199	10.1	47.9	6.8	4.1	11.0	26.0	4.1	1,966	73	509
Disabled	2.6	229	12.8	21.7	30.6	11.9	21.0	11.9	2.9	1,791	5,067	52,125
Adults	1.0	53	10.9	33.8	46.1	9.7	7.9	2.2	0.2	480	12,994	94,615
Children	0.4	23	10.6	41.0	53.1	3.8	1.9	0.2	0.0	220	52,401	480,833
Unknown	1.6	126	13.5	37.5	31.6	11.2	13.2	5.9	0.7	931	152	1,290
Gender												
Female	0.8	49	11.7	34.2	52.0	6.4	5.1	1.9	0.4	416	38,419	338,355
Male	0.6	42	11.4	39.8	50.7	4.6	3.8	1.0	0.1	373	30,467	283,319
Unknown	0.0	0	0.7	98.9	1.1	0.0	0.0	0.0	0.0	62	1,801	7,698
Race												
White	0.8	50	12.3	35.8	51.2	6.1	4.9	1.6	0.3	408	55,008	485,301
African American	0.7	45	11.0	36.9	52.8	4.4	4.4	1.2	0.2	408	1,380	12,427
Other/unknown	0.4	27	8.2	47.8	45.6	3.2	2.6	0.7	0.1	331	14,299	131,644
Use of Nursing Fa	cilities <sup>f</sup>											
Entire year	8.4	560	10.5	3.5	4.7	7.1	15.3	48.2	21.2	5,353	85	757
Part year	5.8	342	6.2	3.2	16.1	12.9	23.7	32.3	11.8	5,516	93	789
None	0.7	44	11.6	38.4	50.2	5.5	4.4	1.3	0.2	380	70,509	627,826
Maintenance Ass	stance Status	5										
Cash	1.2	86	16.6	35.9	43.0	7.4	9.0	3.8	0.8	518	16,437	148,574
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.4	22	12.2	38.1	55.3	4.4	2.1	0.2	0.0	183	37,274	335,838
Other/unknown	0.8	56	7.5	40.9	45.7	6.0	5.2	1.9	0.3	748	16,976	144,960

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>A, b, c</sup>

NONDUAL BENEFICIARIES, WYOMING, 2005

		All Rx		Patented	d Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	d-Name	Gen	eric Dı	uas
Beneficiary	Number			Number			Number			Number		-9-
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.7	\$45	\$65	0.3	\$35	\$130	0.0	\$2	\$72	0.4	\$8	\$21
Age												
5 and younger	0.4	16	44	0.1	12	87	0.0	1	48	0.2	4	17
6-14	0.5	32	72	0.2	27	114	0.0	1	70	0.2	4	21
15-20	0.7	50	73	0.3	40	138	0.0	3	67	0.4	8	21
21-44	1.2	79	64	0.4	59	152	0.1	4	67	0.8	16	20
45-64	3.2	242	75	1.1	180	164	0.1	13	109	2.0	49	24
65-74	3.9	233	60	1.2	158	133	0.1	6	44	2.6	69	27
75-84	3.6	130	37	0.7	71	99	0.1	9	140	2.8	50	18
85 and older	4.1	199	48	1.1	148	136	0.1	3	28	2.9	48	16
Unknown	0.0	0	119	0.0	0	287	0.0	0	9	0.0	0	6
Basis of Eligibility	rd .											
Aged	3.9	199	51	1.1	135	128	0.1	6	53	2.8	59	21
Disabled	2.6	229	89	1.0	181	176	0.1	10	96	1.4	37	26
Adults	1.0	53	51	0.3	37	128	0.0	3	64	0.7	13	18
Children	0.4	23	56	0.2	18	102	0.0	1	60	0.2	4	18
Unknown	1.6	126	79	0.6	93	158	0.0	4	86	1.0	29	30
Gender												
Female	0.8	49	60	0.3	36	130	0.0	3	69	0.5	10	20
Male	0.6	42	73	0.3	34	130	0.0	2	76	0.3	6	22
Unknown	0.0	0	90	0.0	0	483	0.0	0	0	0.0	0	11
Race												
White	0.8	50	66	0.3	39	130	0.0	2	72	0.4	9	21
African American	0.7	45	69	0.3	36	137	0.0	2	62	0.4	7	20
Other/unknown	0.4	27	62	0.2	20	131	0.0	1	71	0.3	6	21
Use of Nursing Fa	cilitiese											
Entire year	8.4	560	67	2.5	419	167	0.3	21	74	5.5	114	21
Part year	5.8	342	59	1.8	236	133	0.2	16	82	3.8	89	23
None	0.7	44	65	0.3	34	130	0.0	2	71	0.4	8	21
Maintenance Assi	stance Sta	tus										
Cash	1.2	86	72	0.4	66	152	0.0	4	84	0.7	16	23
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Poverty related	0.4	22	52	0.2	17	97	0.0	1	57	0.2	4	18
Other/unknown	0.8	56	72	0.3	45	141	0.0	3	74	0.4	9	21

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Wyoming, 1.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>

NONDUAL BENEFICIARIES, WYOMING, 2005

			x per Ben ong User		\$ per	Benefit N Use		nong		\$ per	·Rx					Userse	
Therapeutic Category	F Total	atented Brand- Name	Off- Patent Brand- Name G	Seneric		atented Brand- Name	Off- Patent Brand- Name G	Seneric	P Total	atented Brand- Name	Brand-	Generic	Total Number of Rx	Total Rx \$	Number of	of All	Number of Benefit Months
Anti-infective Agents	0.2	0.1	0.0	0.1	\$9	\$5	\$2	\$3	\$40	\$76	\$60	\$21	75,366	\$3,031,589	31,041	43.9	320,746
Biologicals	0.2	0.2	0.0	0.0	193	179	0	14	868	828	0	2,329	715	620,450	334	0.5	3,220
Antineoplastic Agents	0.5	0.2	0.0	0.3	162	146	0	15	307	697	87	49	825	253,211	150	0.2	1,566
Endocrine/Metabolic Drugs	0.4	0.1	0.0	0.2	24	17	3	5	64	133	66	23	33,807	2,147,534	8,870	12.5	88,877
Cardiovascular Agents	8.0	0.2	0.0	0.6	33	25	0	8	40	100	32	14	27,031	1,087,992	3,261	4.6	33,010
Respiratory Agents	0.3	0.2	0.0	0.2	18	15	1	3	53	89	54	17	69,601	3,671,087	19,579	27.7	204,480
Gastrointestinal Agents	0.3	0.2	0.0	0.2	35	31	0	4	102	179	46	22	16,877	1,728,197	4,879	6.9	49,211
Genitourinary Agents	0.2	0.1	0.0	0.1	12	7	1	3	51	96	62	23	5,528	282,519	2,543	3.6	24,140
CNS Drugs	0.8	0.4	0.0	0.3	78	68	1	8	99	160	142	24	61,775	6,142,739	7,954	11.3	78,723
Stimulants/Anti-obesity/Anorexia	0.8	0.7	0.0	0.1	78	74	0	3	103	112	58	38	24,898	2,566,684	3,111	4.4	32,977
Miscellaneous Psychological/ Neurological Agents Analgesics and Anesthetics	0.5 0.4	0.5	0.0	0.0	334 15	333	0	1	642 37	669 235	0 178	39 18	745 49.106	478,072 1,793,468			1,432 123,360
Neuromuscular Agents	0.6	0.3	0.0	0.3	63	49	3	11	106	179	104	36	25,621	2,716,058	,	6.0	43,435
Nutritional Products	0.2	0.0	0.0	0.2	3	1	0	2	15	41	34	12	10,842	162,103	,	7.7	51,608
Hematological Agents	0.5	0.1	0.0	0.4	72	64	1	7	137	464	33	18	3,674	501,722	,	1.0	7,010
Topical Products	0.2	0.1	0.0	0.1	7	5	0	2	40	81	43	19	27,358	1.101.109	14.266	20.2	151,369
Miscellaneous Products	0.2	0.1	0.0	0.1	12	8	1	3	69	89	264	38	1,918	132,899	1,036	1.5	11,129
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	7	0	0	0	45	0	0	0	534	24,076	,	0.5	3,448
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	436,221	28,441,509		n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Wyoming, 1.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

#### TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

	-		Users		An	nong Usei	rs
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months		\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$3,588,487	2,600	3.7	27,155	0.6	\$232	\$132
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	2,566,690	3,736	5.3	40,017	0.6	103	64
ANTICONVULSANT	2,519,263	2,797	4.0	29,272	0.6	136	86
ANTIASTHMATIC	2,357,901	12,553	17.8	132,850	0.3	71	18
ANTIDEPRESSANTS	2,318,256	7,491	10.6	74,926	0.5	67	31
ULCER DRUGS	982,768	4,495	6.4	45,798	0.3	70	21
ANALGESICS - Narcotic	952,222	14,515	20.5	143,389	0.3	26	7
MISC. ENDOCRINE	889,841	385	0.5	4,266	0.4	477	209
MACROLIDE ANTIBIOTICS	815,582	13,245	18.7	141,095	0.1	44	6
DERMATOLOGICAL	722,157	10,821	15.3	116,217	0.1	46	6
Total	17,713,167	72,638		754,985	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

<sup>=</sup> Medicaid reimbursement.

# TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

All Top 10 Drug Groups **ANTIPSYCHOTICS** STIMULANTS/ANTI-OBESITY/ANOREXIANTS Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx as % Months Rx per Rx \$ per as % Months Rx per \$ per Beneficiary Number of of All Among Benefit Benefit Number of All Among Benefit Benefit Characteristics Number of Rx Rx \$ Users Benes Users Month Month of Users Benes Users Month Month 213,310 \$17,713,167 \$132 ΑII 2.600 3.7 27,155 0.6 3.736 5.3 40,017 0.6 \$64 Female 12,378 All Females 124,265 9,312,715 1,366 3.6 14,108 0.5 118 1,154 0.6 3.0 63 Female, Disabled 42,532 4,257,146 22.4 6,635 0.6 213 7.9 0.7 79 All Ages 600 169 2,449 35 2 5 and younger 681 43.918 0.8 12 0.6 1.6 24 0.6 46 1 6-14 2,787 370,839 489 131 84 983 0.7 41 14.4 0.6 29.6 70 15-20 2.712 380.441 53 22.5 598 0.7 158 40 16.9 445 0.8 87 21-44 13,386 1,335,426 236 25.1 2,517 0.6 164 48 5.1 551 0.6 68 45-64 22,966 2,126,522 269 24.6 3,019 0.7 182 39 3.6 446 0.5 106 65-74 0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 75-84 0 0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0.0 0 0 0 0 85 and older 0.0 0.0 0 0.0 Female, Other Eligibles 7,473 59 All Ages 81,732 5,055,560 766 2.1 0.4 72 941 2.6 9,929 0.6 5 and younger 10.958 510.657 14 0.1 159 0.3 73 46 0.4 492 0.4 32 6-14 16,654 1,284,138 128 1.3 1,388 0.5 89 586 6.1 6,346 0.6 59 1,024,359 15-20 15,147 239 4.2 2,463 0.4 79 136 2.4 1,414 0.6 63 21-44 34,627 1,932,686 340 3.6 3,071 0.3 59 156 1.6 1,524 0.5 66 45-64 3,879 272,590 40 6.9 340 0.4 51 17 2.9 153 0.4 40 65-74 7.1 2.1 438 0 0.0 0 0.0 0 254 16,775 11 75-84 59 3,489 2 13.3 24 0.6 112 0 0.0 0 0.0 0 85 and older 154 10,866 2 12.5 17 1.1 198 0 0.0 0 0.0 0 Male All Males 89,033 8,400,288 1.234 13,047 2.582 27,639 4.1 0.6 148 8.5 0.6 65 Male. Disabled 26,803 6,433 190 309 13.0 3,454 82 All Ages 3,395,184 593 24.9 0.7 8.0 3 6 24 5 and younger 649 65,713 1.8 36 1.0 128 3.6 29 0.4 5,647 6-14 752.178 102 22.0 1.170 0.7 164 169 36.4 1.932 0.8 81 15-20 4,426 715,537 133 34.5 1,489 0.7 174 88 22.8 986 0.7 78 21-44 36 8,817 1,168,061 254 34.2 2,758 0.7 209 4.8 414 0.7 96 45-64 693,695 83 7,264 101 16.2 980 0.7 192 10 1.6 93 0.5 0 0.0 0 65-74 0 0 0.0 0 0 0 0.0 0 0.0 75-84 0 0 0 0 0 0 0.0 0.0 0 0.0 0 0.0 85 and older 0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0

# TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

	All Top 10	Drug Groups		ANT	IPSYCHOTIC	S		STIMUL	ANTS/A	NTI-OBESIT	Y/ANOREX	(IANTS
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Iumber of Rx per I Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Months Among	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	62,230	5,005,104	641	2.3	6,614	0.5	108	2,273	8.1	24,185	0.6	62
5 and younger	15,055	771,385	14	0.1	148	0.5	82	107	1.0	1,172	0.3	28
6-14	28,097	2,534,055	296	2.9	3,169	0.6	111	1,686	16.5	17,960	0.6	63
15-20	12,938	1,303,594	277	6.2	2,816	0.6	107	443	9.9	4,713	0.6	67
21-44	4,675	301,949	43	2.2	380	0.3	78	34	1.7	304	0.6	85
45-64	1,123	66,616	5	1.4	38	0.5	120	3	0.9	36	0.1	33
65-74	190	15,715	2	20.0	24	1.0	257	0	0.0	0	0.0	0
75-84	75	3,148	1	14.3	3	0.7	259	0	0.0	0	0.0	0
85 and older	77	8,642	3	30.0	36	0.6	141	0	0.0	0	0.0	0
Unknown	13	173	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

## ${\sf TABLE\;ND.7B}\\ {\sf MEDICAID\;PHARMACY\;BENEFIT\;USE\;AND\;REIMBURSEMENT\;FOR\;THIRD\;TO\;FIFTH\;TOP\;DRUG\;GROUPS\;SEPARATELY,}$

#### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

		ANTI	CONVULSA			THE TOP WILL		ΓΙΑSTΗΜΑΤΙ	С			ANTI	DEPRESSAN	TS	
	Number of	Users as % of All	Number of Benefit N Months Among	Mean Number of Rx per F Benefit		Number of	Users as % of All	Number of Benefit N Months Among	Mean Number of Rx per Benefit	Mean Rx \$ per	Number of	Users as % of All	Number of Benefit N Months Among		Mean Rx \$ per Benefit
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	
All	2,797	4.0	29,272	0.6	\$86	12,553	17.8	132,850	0.3	\$18	7,491	10.6	74,926	0.5	
Female															
All Females	1,785	4.6	18,469	0.6	82	6,621	17.2	69,175	0.3	18	5,410	14.1	53,227	0.4	31
Female, Disabled															
All Ages	877	32.7	9,643	0.8	106	1,120	41.7	12,391	0.4	32	1,441	53.7	15,726	0.6	37
5 and younger	25	19.5	275	0.5	31	56	43.8	645	0.3	27	2	1.6	24	0.6	4
6-14	73	25.7	851	0.8	135	77	27.1	881	0.3	26	50	17.6	590	0.6	26
15-20	79	33.5	878	0.9	181	46	19.5	539	0.2	15	99	41.9	1,110	0.5	28
21-44	321	34.1	3,479	0.7	104	285	30.3	3,093	0.3	20	537	57.1	5,822	0.5	37
45-64	379	34.6	4,160	0.8	90	656	60.0	7,233	0.5	39	753	68.8	8,180	0.6	39
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	908	2.5	8,826	0.4	55	5,501	15.4	56,784	0.2	15	3,969	11.1	37,501	0.4	28
5 and younger	27	0.3	300	0.3	26	1,586	15.4	17,166	0.2	12	7	0.1	69	0.4	13
6-14	115	1.2	1,164	0.5	74	1,470	15.3	16,000	0.2	17	411	4.3	4,485	0.5	24
15-20	178	3.1	1,816	0.5	72	909	16.1	9,407	0.2	12	945	16.7	9,468	0.4	25
21-44	518	5.4	4,875	0.4	47	1,409	14.8	12,946	0.3	17	2,368	24.8	21,305	0.4	29
45-64	63	10.9	599	0.4	51	115	19.9	1,146	0.4	26	226	39.1	2,056	0.5	40
65-74	4	28.6	43	0.7	46	11	78.6	110	0.7	36	7	50.0	66	0.7	39
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	13.3	24	0.6	14
85 and older	3	18.8	29	1.5	78	1	6.3	9	0.1	14	3	18.8	28	1.1	71
Male															
All Males	1,012	3.3	10,803	0.7	94	5,929	19.5	63,655	0.2	18	2,081	6.8	21,699	0.5	32
Male, Disabled															
All Ages	575	24.1	6,446	0.8	111	628	26.4	6,829	0.4	33	689	28.9	7,390	0.6	39
5 and younger	14	8.5	161	0.6	124	83	50.3	886	0.2	18	1	0.6	5	0.8	6
6-14	115	24.8	1,352	8.0	119	151	32.5	1,780	0.4	35	89	19.2	998	0.6	31
15-20	101	26.2	1,133	0.8	136	63	16.3	670	0.3	17	117	30.3	1,309	0.7	45
21-44	218	29.3	2,449	0.9	106	129	17.4	1,442	0.3	28	256	34.5	2,721	0.6	42
45-64	127	20.4	1,351	0.7	89	202	32.4	2,051	0.5	46	226	36.2	2,357	0.6	35
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

### TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

#### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

		ANTI	CONVULSA	NT			ANT	TASTHMATIC	0			ANTI	DEPRESSAN	TS	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months		Rx \$ per		as %	Months		Rx \$ per		as %	Months		Rx \$ per
Panafician, Characteristics	Number of	of All	Among	Benefit		Number of	of All	Among	Benefit	Benefit	Number of	of All	Among		Benefit
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Eligibles															
All Ages	437	1.6	4,357	0.5	68	5,301	18.9	56,826	0.2	16	1,392	5.0	14,309	0.5	29
5 and younger	47	0.4	518	0.4	38	2,515	22.7	27,336	0.2	13	15	0.1	151	0.2	6
6-14	181	1.8	1,932	0.5	73	2,006	19.7	21,549	0.3	18	555	5.4	6,029	0.5	23
15-20	124	2.8	1,199	0.5	73	576	12.9	6,066	0.3	18	543	12.2	5,507	0.5	34
21-44	62	3.1	494	0.5	75	163	8.2	1,511	0.3	21	214	10.8	1,977	0.4	33
45-64	22	6.4	202	0.5	45	33	9.6	280	0.3	18	55	15.9	531	0.4	33
65-74	1	10.0	12	1.0	224	3	30.0	32	0.6	13	7	70.0	80	0.8	33
75-84	0	0.0	0	0.0	0	2	28.6	18	0.8	16	1	14.3	10	1.0	41
85 and older	0	0.0	0	0.0	0	3	30.0	34	0.6	58	2	20.0	24	0.6	43
Unknown	0	0.0	0	0.0	0	3	0.2	20	0.2	2	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## ${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

#### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

		ULO	CER DRUGS					SESICS - Nar				MISC	. ENDOCRIN	ΝE	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users			Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month
All	4,495	6.4	45,798	0.3	\$22	14,515	20.5	143,389	0.3	\$7		0.5	4,266	0.4	
Female	.,		,		*	,		,		•			-,	-	*
All Females	2,998	7.8	30,446	0.3	21	10,740	28.0	104,252	0.3	7	198	0.5	2,204	0.4	134
Female, Disable			,			,.		,					_,,	-	
All Ages	830	30.9	9,188	0.5	32	1,785	66.5	19,676	0.4	18	116	4.3	1,309	0.4	136
5 and younger	31	24.2	341	0.4	25	20	15.6	229	0.1	2		2.3	36	0.2	
6-14	34	12.0	388	0.4	24	39	13.7	454	0.1	1	9	3.2	108	0.5	
15-20	37	15.7	422	0.4	35	54	22.9	617	0.2			3.0	81	0.5	
21-44	250	26.6	2,771	0.4	30	697	74.1	7,683	0.4	16		1.8	190	0.4	
45-64	478	43.7	5,266	0.5	34	975	89.1	10,693	0.5		80	7.3	894	0.5	
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0			0.0	0	0.0	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	ligibles														
All Ages	2,168	6.1	21,258	0.2	17	8,955	25.1	84,576	0.2	4	82	0.2	895	0.3	132
5 and younger	327	3.2	3,216	0.2	12	364	3.5	4,067	0.1	1	4	0.0	47	0.1	23
6-14	282	2.9	3,185	0.2	13	787	8.2	8,626	0.1	1	37	0.4	420	0.4	221
15-20	485	8.6	5,039	0.2	14	1,886	33.3	18,755	0.2	2	4	0.1	46	0.4	154
21-44	969	10.1	8,814	0.3	20	5,577	58.4	49,695	0.3	5	17	0.2	184	0.3	53
45-64	99	17.1	935	0.4	32	328	56.7	3,306	0.4	16	17	2.9	167	0.4	31
65-74	4	28.6	48	0.8	46	8	57.1	86	0.5	14	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	3	20.0	25	1.0	12	0	0.0	0	0.0	0
85 and older	2	12.5	21	1.0	19	2	12.5	16	1.1	17	3	18.8	31	0.5	70
Male															
All Males	1,496	4.9	15,346	0.3	22	3,774	12.4	39,126	0.2	7	187	0.6	2,062	0.5	288
Male, Disabled															
All Ages	406	17.0	4,343	0.5	34	816	34.2	8,650	0.4	19	53	2.2	608	0.6	460
5 and younger	25	15.2	261	0.3	24	15	9.1	171	0.1	1	3	1.8	36	0.6	353
6-14	41	8.8	484	0.4	38	78	16.8	898	0.1	2	17	3.7	196	0.6	574
15-20	36	9.3	412	0.4	30	79	20.5	901	0.2	6	14	3.6	155	0.6	777
21-44	129	17.4	1,407	0.5	36	281	37.8	2,939	0.4	12	12	1.6	142	0.5	216
45-64	175	28.0	1,779	0.5	34	363	58.2	3,741	0.5	32	7	1.1	79	0.5	41
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

### TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

## BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

		UL	CER DRUGS				ANALO	SESICS - Nar	cotic			MIS	C. ENDOCRIN	ΝE	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N		Mean		Users		lumber of	Mean		Users		Number of	Mean
D	Ni is a su of	as %	Months		Rx \$ per	Niversity and	as %	Months		Rx \$ per	Ni walan af	as %			Rx \$ per
Beneficiary Characteristics	Number of Users	of All Benes	Among Users	Benefit Month	Month	Number of Users	of All Benes	Among Users	Benefit Month	Benefit Month	Number of Users	of All Benes	- 3	Benefit Month	
Characteristics	USEIS	Delles	USEIS	MOHIT	MOHILII	USEIS	Delles	USEIS	MOHIT	WOTH	USEIS	Denes	USEIS	MOHUI	IVIOTILIT
Male, Other Elig	ibles														
All Ages	1,090	3.9	11,003	0.2	17	2,958	10.5	30,476	0.2	4	134	0.5	1,454	0.4	217
5 and younger	511	4.6	5,008	0.2	12	507	4.6	5,624	0.1	1	8	0.1	86	0.4	122
6-14	233	2.3	2,575	0.2	16	790	7.7	8,716	0.1	1	107	1.0	1,170	0.4	148
15-20	163	3.7	1,752	0.2	20	816	18.3	8,529	0.1	1	15	0.3	157	0.6	823
21-44	140	7.0	1,241	0.3	24	690	34.7	6,174	0.3	11	2	0.1	21	0.2	44
45-64	34	9.9	323	0.4	38	146	42.3	1,350	0.4	10	1	0.3	8	0.4	78
65-74	5	50.0	60	0.8	44	5	50.0	52	0.3	7	1	10.0	12	0.8	61
75-84	2	28.6	22	1.0	38	4	57.1	31	0.8	26	0	0.0	0	0.0	0
85 and older	2	20.0	22	0.6	14	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	1	0.1	6	0.2	2	1	0.1	11	0.1	1	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE ND.7D

#### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>
NONDUAL BENEFICIARIES, WYOMING, 2005

MACROLIDE ANTIBIOTICS DERMATOLOGICAL Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx per Rx \$ per as % Months as % Months Rx per Rx \$ per Beneficiary Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of Number of Characteristics Benes Users Beneficiaries Benefit Months Users Users Month Month Benes Users Month Month ΑII 13.245 18.7 141.095 0.1 \$6 10.821 15.3 116,217 0.1 \$6 70.687 629.372 **Female** All Females 7,508 19.5 78,689 0.1 6 6,147 16.0 65,167 0.1 6 38,416 338,350 Female, Disabled All Ages 666 24.8 7,536 0.1 7 668 24.9 7,624 0.2 10 2,684 27,914 55 0.2 6 5 and younger 43.0 645 43 33.6 507 0.1 4 128 1,296 76 52 6-14 26.8 867 0.1 6 18.3 608 0.1 6 284 3,096 15-20 54 22.9 617 0.1 7 56 23.7 656 0.1 7 236 2.551 7 940 21-44 208 22.1 2,337 0.1 209 22.2 2,401 0.2 8 9,789 45-64 273 25.0 3,070 0.1 8 308 28.2 3,452 0.2 13 1,094 11,179 2 65-74 0 0.0 0 0.0 0 0 0.0 0 0.0 0 3 0 75-84 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0 85 and older 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 Female, Other Eligibles All Ages 6,842 19.1 71,153 0.1 6 5,478 15.3 57,542 0.1 6 35,732 310,436 2,349 22.9 25,407 0.1 5 2,314 22.5 24,893 0.1 10,274 96,068 5 and younger 1,599 16.6 17,595 0.1 6 1,225 12.7 13,498 0.1 6 9,620 92,029 6-14 15-20 1,095 19.3 11,311 0.1 6 929 16.4 9,702 0.1 9 5,663 47,833 21-44 1,678 17.6 15,650 0.1 7 922 9.7 8,579 0.2 8 9,552 69,445 45-64 118 20.4 1,156 0.1 8 81 14.0 799 0.1 12 578 4,769 65-74 7.1 11 0.2 11 2 14.3 23 0.1 2 14 127 75-84 1 6.7 12 0.1 4 2 13.3 24 0.2 6 15 81 85 and older 1 6.3 11 0.2 6 3 18.8 24 0.3 10 16 84 Male All Males 5,735 18.8 62,383 4,670 51,036 0.1 6 30,466 283,315 0.1 6 15.3 Male. Disabled All Ages 413 17.3 4,732 7 514 21.6 0.2 8 2,383 24,211 0.1 5,889 48 29.1 517 0.2 6 51 30.9 165 1,706 5 and younger 583 0.1 5 6-14 122 26.3 1,431 0.1 7 96 20.7 1,121 0.1 5 464 5,149 15-20 65 16.8 763 0.1 6 114 29.5 1,349 0.2 10 386 4,107 21-44 108 14.5 1.258 0.1 7 145 19.5 1,662 0.2 8 743 7,375 45-64 70 11.2 763 0.1 7 108 17.3 1,174 0.2 11 624 5,873 65-74 0 0.0 0 0.0 0 0 0.0 0 0.0 0 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0 0.0 0 0 0 85 and older 0 0.0 0 0.0 0 0 0.0

#### TABLE ND.7D

#### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

### SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

		MACRO	LIDE ANTIBIC	TICS			DER	MATOLOGICA	٩L			
		Users	Number of Benefit N	Mean lumber of	Mean		Users	Number of Benefit N	Mean lumber of	Mean		
		as %	Months	Rx per I	Rx \$ per		as %		Rx per l	Rx \$ per		
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries E	Benefit Months
Male, Other Eligi	bles											
All Ages	5,322	19.0	57,651	0.1	6	4,156	14.8	45,147	0.1	6	28,083	259,104
5 and younger	2,946	26.6	32,079	0.1	5	2,323	21.0	25,216	0.1	4	11,069	104,947
6-14	1,581	15.5	17,251	0.1	5	1,044	10.2	11,582	0.1	6	10,196	97,450
15-20	580	13.0	6,221	0.1	6	693	15.5	7,417	0.2	12	4,458	39,365
21-44	173	8.7	1,693	0.1	7	75	3.8	729	0.2	6	1,988	14,368
45-64	39	11.3	377	0.1	7	18	5.2	173	0.2	4	345	2,758
65-74	1	10.0	8	0.1	6	1	10.0	12	0.1	5	10	101
75-84	0	0.0	0	0.0	0	1	14.3	6	0.2	5	7	47
85 and older	2	20.0	22	0.1	10	1	10.0	12	0.5	5	10	68
Unknown	2	0.1	23	0.1	3	5	0.3	15	0.3	3	1,805	7,707

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = Deneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

#### TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>

### NONDUAL BENEFICIARIES, WYOMING, 2005

Danafisian		Number of Dynas Deposit	Number of All Veer Number	Benefit Months Among All-
Beneficiary Characteristics	Rx \$ per Benefit Month	Month	Number of All-Year Nursing Facility Residents	Year Nursing Facility Residents
All	\$560	8.4		757
Age				
0-64	609	8.9	67	614
65-74	599	7.2	3	29
75-84	276	6.0	5	36
85 and older	290	5.7	10	78
Unknown	0	0.0	0	0
Gender				
Female	542	9.1	44	407
Male	581	7.5	41	350
Unknown	0	0.0	0	0
Race				
White	542	8.2	69	602
African American	1641	38.3	1	12
Other/unknown	544	6.5	15	143
Basis of Eligibility	;			
Aged	349	6.1	18	143
Disabled	609	8.9	67	614
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 93 beneficiaries who were in

nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

c. inedicate basis or eligibility is classified as, aged, disabled, adultis, and children't ne disabled group includes behaliciant or all yage who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicard Services; MAX = Medicard Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicard reimbursement.

#### TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

#### BY BRAND STATUS AND THERAPEUTIC CATEGORYA, b, c, d, e NONDUAL BENEFICIARIES, WYOMING, 2005

Number of Rx per Benefit \$ per Benefit Month Among Month Among Users Users \$ per Rx Users

Therapeutic Category	P	atented Brand- Name	Brand-	Generic	P Total		Off- Patent Brand- Name G	eneric	P Total	atented Brand- Name	Off- Patent Brand- Name G	eneric	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.6	0.2	0.0	0.4	\$36	\$19	\$6	\$11	\$62	\$120	\$154	\$28	338	\$20,938	60	70.6	582
Biologicals	0.1	0.1	0.0	0.0	2	1	0	1	22	16	0	35	3	67	3	3.5	36
Antineoplastic Agents	1.0	1.0	0.0	0.0	1,347	1,347	0	0	1406	1,406	0	0	23	32,338	2	2.4	24
Endocrine/Metabolic Drugs	1.3	0.3	0.2	0.8	50	35	4	12	37	106	18	14	549	20,427	43	50.6	410
Cardiovascular Agents	2.3	0.5	0.0	1.8	75	47	0	27	32	95	42	15	1,057	33,994	54	63.5	456
Respiratory Agents	1.2	0.9	0.0	0.3	81	74	1	6	68	86	20	19	393	26,547	35	41.2	328
Gastrointestinal Agents	1.2	0.3	0.1	0.8	48	29	3	16	41	105	26	21	504	20,892	45	52.9	433
Genitourinary Agents	1.1	0.6	0.0	0.5	69	57	2	10	62	100	70	19	231	14,262	21	24.7	208
CNS Drugs	1.7	0.9	0.0	0.8	174	157	0	17	104	173	55	22	1,090	112,938	71	83.5	650
Stimulants/Anti-obesity/Anorexia	0.5	0.4	0.0	0.1	74	73	0	1	161	194	0	14	11	1,770	3	3.5	24
Miscellaneous Psychological/ Neurological Agents	0.8	0.5	0.0	0.3	463	451	0	12	573	837	0	45	42	24,067	5	5.9	52
Analgesics and Anesthetics	1.5	0.1	0.0	1.4	92	44	16	32	61	511	491	23	683	41,631	50	58.8	454
Neuromuscular Agents	1.4	0.3	0.0	1.0	120	69	2	50	88	203	150	49	446	39,037	30	35.3	325
Nutritional Products	0.9	0.0	0.0	0.9	15	0	1	14	16	6	20	16	243	3,925	27	31.8	263
Hematological Agents	1.5	0.3	0.0	1.3	66	55	0	11	44	216	5	9	428	18,624	30	35.3	284
Topical Products	0.5	0.1	0.0	0.3	18	11	1	6	37	78	49	19	171	6,351	36	42.4	354
Miscellaneous Products	0.9	0.0	0.0	0.9	6	0	0	6	7	7	0	7	91	650	9	10.6	101
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	65	0	0	0	243	0	0	0	22	5,356	9	10.6	83
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	6,325	423,814	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Wyoming, 1.1 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

#### BY TOP-10 DRUG GROUPa, b, c, d NONDUAL BENEFICIARIES, WYOMING, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthspo	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$79,790	38	44.7	405	0.9	\$211	\$197
ANTINEOPLASTICS	32,338	2	2.4	24	1.0	1406	1,347
ANTIDEPRESSANTS	28,959	60	70.6	592	0.8	61	49
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	24,067	5	5.9	52	0.8	573	463
ANTIASTHMATIC	21,432	38	44.7	351	0.7	85	61
ANTICONVULSANT	21,384	26	30.6	289	0.9	78	74
ANALGESICS - Narcotic	20,492	59	69.4	543	0.9	40	38
ANALGESICS - ANTI-INFLAMMATORY	18,902	23	27.1	211	0.6	154	90
ANTIHYPERLIPIDEMIC	16,780	15	17.6	143	1.1	110	117
ULCER DRUGS	15,323	46	54.1	455	0.8	41	34
Total	279,467	312		3,065	n.a.	n.a.	n.a.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

#### TABLE ND.10A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, WYOMING, 2005

	All Top 10 Di	ug Groups		ANTIPS	CHOTICS				ANTINE	OPLASTICS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents				Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	Mean Rx \$
All	2,601	\$279,467	38	44.7	405	0.9	\$197	2	2.4	24	1.0	\$1,347
Female												
All Females	1,514	141,138	19	43.2	211	0.9	185	1	2.3	12	1.0	243
Female, Disabled												
All Ages	1,308	122,001	14	41.2	159	0.9	178	1	2.9	12	1.0	243
64 or younger	1,308	122,001	14	41.2	159	0.9	178	1	2.9	12	1.0	243
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	206	19,137	5	50.0	52	1.1	209	0	0.0	0	0.0	0
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	75	8,661	1	50.0	11	2.1	438	0	0.0	0	0.0	0
75-84	39	3,283	2	66.7	24	0.6	112	0	0.0	0	0.0	0
85 and older	92	7,193	2	40.0	17	1.1	198	0	0.0	0	0.0	0
Male												
All Males	1,087	138,329	19	46.3	194	0.9	210	1	2.4	12	0.9	2,452
Male, Disabled												
All Ages	960	125,031	15	45.5	155	1.0	225	1	3.0	12	0.9	2,452
64 or younger	960	125,031	15	45.5	155	1.0	225	1	3.0	12	0.9	2,452
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	127	13,298	4	50.0	39	0.6	150	0	0.0	0	0.0	0
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	20	754	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	31	2,480	1	50.0	3	0.7	259	0	0.0	0	0.0	0
85 and older	76	10,064	3	60.0	36	0.6	141	0	0.0	0	0.0	0
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were

a. Table No. Those includes a fee included a fee included and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state. d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BDE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE ND.10B

#### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-VEAD NURSING EACH ITY DESIDENTS BY SEY BASIS OF ELIGIBILITY AND AGEA, b. C. d

		Al	MONG ALL-YE	AR NUR		NDUAL BENEI	ENTS, BY SEX FICIARIES, WY	OMING, 2005		Y, AND	AGE <sup>a, b, c, d</sup>				
		ANTIDEP	RESSANTS			MIS	C PSYCHOTI NEURO	HERAPEUTIO LOGICAL	CAND			ANTIAS	THMATIC		
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among I	Mean Number of Rx	
All	60	70.6	592	0.8	\$49	5	5.9	52	0.8	\$463	38	44.7	351	0.7	\$61
Female															
All Females	38	86.4	370	0.8	48	4	9.1	40	0.8	556	22	50.0	202	0.7	59
Female, Disable	ed														
All Ages	33	97.1	324	0.8	46	4	11.8	40	0.8	556	18	52.9	173	0.7	57
64 or younger	33	97.1	324	0.8	46	4	11.8	40	0.8	556	18	52.9	173	0.7	57
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	Eligibles														
All Ages	5	50.0	46	0.8	67	0	0.0	0	0.0	0	4	40.0	29	0.7	69
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	2	100.0	17	0.9	87	0	0.0	0	0.0	0	4	200.0	29	0.7	69
75-84	1	33.3	12	0.3	19	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	2	40.0	17	0.9	80	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male															
All Males	22	53.7	222	0.8	50	1	2.4	12	0.9	152	16	39.0	149	0.7	64
Male, Disabled															
All Ages	20	60.6	198	0.8	49	0	0.0	0	0.0	0	13	39.4	119	0.8	64
64 or younger	20	60.6	198	0.8	49	0	0.0	0	0.0	0	13	39.4	119	0.8	64
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Elig	gibles														
All Ages	2	25.0	24	0.8	59	1	12.5	12	0.9	152	3	37.5	30	0.7	66
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

0.0 Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

0.0

40.0

0

2

0

75-84

Unknown

85 and older

0.0

0.6

0.0

0

43

0

0

1

0

0.0

20.0

0.0

0

12

0

0.0

0.9

0.0

0

0

152

1

2

0

50.0

40.0

0.0

6

24

0

0.2

8.0

0.0

4

0

81

0

24

0

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state. d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE ND.10C

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, WYOMING, 2005

		ANTICO	NVULSANT				ANALGES	ICS - Narco	tic		ANALO	GESICS - AI	NTI-INFLAM	MATORY	1
Beneficiary Characteristics	Number of Users	Year Nursing Facility				Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users			Number of Users	Users as % of All- Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	
All	26	30.6	289	0.9		59		543	0.9		23	27.1	211	0.6	
Female															
All Females	18	40.9	206	1.0	74	32	72.7	312	1.0	48	12	27.3	112	0.5	
Female, Disable	d														
All Ages	13	38.2	155	1.0	81	29	85.3	284	1.0	52	11	32.4	100	0.5	
64 or younger	13	38.2	155	1.0	81	29	85.3	284	1.0	52	11	32.4	100	0.5	
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
Female, Other E	ligibles														
All Ages	5	50.0	51	1.1	51	3	30.0	28	0.7	10	1	10.0	12	0.6	13
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
65-74	2	100.0	22	0.6	16	1	50.0	11	0.1	1	0	0.0	0	0.0	) (
75-84	0	0.0	0	0.0	0	1	33.3	12	1.3	19	1	33.3	12	0.6	13
85 and older	3	60.0	29	1.5	78	1	20.0	5	0.6	8	0	0.0	0	0.0	) (
Male															
All Males	8	19.5	83	0.8	74	27	65.9	231	0.8	24	11	26.8	99	0.6	182
Male, Disabled															
All Ages	8	24.2	83	0.8	74	25	75.8	222	0.8	22	11	33.3	99	0.6	182
64 or younger	8	24.2	83	0.8	74	25	75.8	222	0.8	22	11	33.3	99	0.6	182
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	) (
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
Male, Other Elig	ibles														
All Ages	0	0.0	0	0.0	0	2	25.0	9	1.1	74	0	0.0	0	0.0	) (
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	) (
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	) (
75-84	0	0.0	0	0.0	0	2	100.0	9	1.1	74	0	0.0	0	0.0	) (
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	)
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE ND.10D

#### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>

NONDUAL BENEFICIARIES, WYOMING, 2005

**ANTIHYPERLIPIDEMIC** 

ULCER DRUGS

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	15	17.6	143	1.1	\$117	46	54.1	455	0.8	\$34	85	757
Female												
All Females	9	20.5	82	1.0	111	25	56.8	234	0.7	30	44	407
Female, Disable	ed											
All Ages	9	26.5	82	1.0	111	24	70.6	222	0.7	31	34	327
64 or younger	9	26.5	82	1.0	111	24	70.6	222	0.7	31	34	327
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other E	ligibles											
All Ages	0	0.0	0	0.0	0	1	10.0	12	1.0	14	10	80
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	17
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	27
85 and older	0	0.0	0	0.0	0	1	20.0	12	1.0	14	5	36
Male												
All Males	6	14.6	61	1.2	126	21	51.2	221	0.9	38	41	350
Male, Disabled												
All Ages	6	18.2	61	1.1	117	19	57.6	197	0.8	37	33	287
64 or younger	6	18.2	61	1.1	117	19	57.6	197	0.8	37	33	287
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	ibles											
All Ages	0	0.0	0	0.0	0	2	25.0	24	1.5	43	8	63
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	1	100.0	12	1.7	63	1	12
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	9
85 and older	0	0.0	0	0.0	0	1	20.0	12	0.8	17	5	42
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 93 beneficiaries who were in nursing facilities for part of their enrollment and their 789 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

#### TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTICa,b WYOMING, 2005

	Number of Beneficiaries with at Least			Total Number					Total Number
Beneficiary Characteristics	One Part D Excluded Rx	One Part D Excluded Rx	per Beneficiary	Part D Excluded Rx	\$ per Beneficiary	Total Part D Excluded Rx \$		ercentage of All Nondual Rx \$	of Beneficiaries
All	18,282	25.9	0.8	55,713	\$22	\$1,550,509	\$28	5.5	70,687
Age									
5 and younger	6,717	30.3	0.6	13,384	14	308,213	23	9.1	22,162
6-14	4,333	21.1	0.5	10,088	21	437,172	43	6.9	20,565
15-20	2,414	22.5	0.5	5,868	16	176,606	30	3.8	10,743
21-44	3,581	27.1	1.2	15,891	30	403,087	25	5.1	13,223
45-64	1,209	45.8	3.8	10,090	83	218,543	22	3.7	2,641
65-74	13	48.1	8.9	239	191	5,149	22	9.5	27
75-84	8	36.4	4.2	92	35	775	8	4.7	22
85 and older	7	26.9	2.3	61	37	964	16	3.2	26
Unknown	0	0.0	0.0	0	0	0	0	0.0	1,278
Basis of Eligibility	С								
Aged	28	38.4	5.4	392	94	6,888	18	6.8	73
Disabled	2,378	46.9	4.2	21,511	180	910,102	42	7.6	5,067
Adults	3,168	24.4	0.7	9,662	12	157,666	16	3.2	12,994
Children	12,656	24.2	0.5	23,931	9	471,841	20	4.2	52,401
Unknown	52	34.2	1.4	217	26	4,012	18	2.5	152
Gender									
Female	10,745	28.0	0.9	34,663	22	852,881	25	5.2	38,419
Male	7,534	24.7	0.7	21,047	23	697,607	33	5.8	30,467
Unknown	3	0.2	0.0	3	0	21	7	0.6	1,801
Race									
White	14,616	26.6	0.8	46,139	23	1,288,227	28	5.3	55,008
African American	377	27.3	0.7	927	16	21,976	24	3.9	1,380
Other/unknown	3,289	23.0	0.6	8,647	17	240,306	28	6.7	14,299
Use of Nursing Fa	cilities <sup>d</sup>								
Entire year	60	70.6	9.0	767	151	12,859	17	3.0	85
Part year	70	75.3	7.5	701	141	13,087	19	4.8	93
None	18,152	25.7	0.8	54,245	22	1,524,563	28	5.5	70,509
Maintenance Assis	stance Status								
Cash	5,079	30.9	1.4	23,277	42	688,936	30	5.4	16,437
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	8,840	23.7	0.4	16,457	9	322,112	20	4.3	37,274
Other/unknown	4,363	25.7	0.9	15,979	32	539,461	34	6.6	16,976

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

# TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup> WYOMING, 2005

Beneficiary ! Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$2	\$28	\$0	\$0	629,372
Age						
5 and younger	0.1	1	23	0	0	207,058
6-14	0.1	2	43	0	0	197,736
15-20	0.1	2	30	0	0	93,856
21-44	0.2	4	25	0	1	100,977
45-64	0.4	9	22	0	2	24,579
65-74	1.0	22	22	0	3	232
75-84	0.7	6	8	0	0	128
85 and older	0.4	6	16	0	1	152
Unknown	0.0	0	0	0	0	4,654
Basis of Eligibility <sup>c</sup>						
Aged	0.8	14	18	0	1	509
Disabled	0.4	17	42	0	2	52,125
Adults	0.1	2	16	0	0	94,615
Children	0.0	1	20	0	0	480,833
Unknown	0.2	3	18	0	0	1,290
Gender						
Female	0.1	3	25	0	0	338,355
Male	0.1	2	33	0	0	283,319
Unknown	0.0	0	7	0	0	7,698
Race						
White	0.1	3	28	0	0	485,301
African American	0.1	2	24	0	0	12,427
Other/unknown	0.1	2	28	0	0	131,644
Use of Nursing Facil	ities <sup>d</sup>					
Entire year	1.0	17	17	0	3	757
Part year	0.9	17	19	0	2	789
None	0.1	2	28	0	0	627,826
Maintenance Assista	nce Status					
Cash	0.2	5	30	0	1	148,574
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	1	20	0	0	335,838
Other/unknown	0.1	4	34	0	0	144,960

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS $^{a,b,c}$  WYOMING, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	22,656	\$68	\$1,550,509	100.0	55,713	\$28	100.0
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	1	339	339	0.0	1	339	0.0
Drugs for cosmetic purposes	31	15	473	0.0	41	12	0.1
Cough and cold medications	10,905	32	344,402	22.2	17,735	19	31.8
Vitamins and minerals	1,625	39	63,465	4.1	4,066	16	7.3
Non-prescription drugs	7,728	120	924,072	59.6	23,546	39	42.3
Barbiturates	74	48	3,567	0.2	483	7	0.9
Benzodiazepines	1,965	75	148,267	9.6	9,053	16	16.2
Other Part D Excl Rx Drugs	327	202	65,924	4.3	788	84	1.4

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who sused drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

			Number of			ARIES, WYOMING,	2005	Number of Benefit Months					
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled		Children	Other/ Unknown	
All	70,687	73		12,994	52,401		629,372	509		94,615	480,833	1,290	
Age	,		,	•	,		•		,	•	,	•	
5 and younger	22,162	0	293	0	21,869	0	207,058	0	3,002	0	204,056	0	
6-14	20,565	0	748	0	19,817	0	197,736	0	8,245	0	189,491	0	
15-20	10,743	0	622	716	9,401	4	93,856	0	6,658	4,794	82,377	27	
21-44	13,223	0	1,683	11,422	38	80	100,977	0	17,164	82,898	258	657	
45-64	2,641	0	1,718	855	0	68	24,579	0	17,052	6,921	0	606	
65-74	27	24	3	0	0	0	232	228	4	0	0	0	
75-84	22	22	0	0	0	0	128	128	0	0	0	0	
85 and older	26	26	0	0	0	0	152	152	0	0	0	0	
Unknown	1,278	1	0	1	1,276	0	4,654	1	0	2	4,651	0	
Gender													
Female	38,419	46	2,684	10,611	24,926	152	338,355	293	27,914	77,217	231,641	1,290	
Male	30,467	27	2,383	2,383	25,674	0	283,319	216	24,211	17,398	241,494	0	
Unknown	1,801	0	0	0	1,801	0	7,698	0	0	0	7,698	0	
Race													
White	55,008	60	4,044	10,400	40,363	141	485,301	407	41,742	74,212	367,724	1,216	
African American	1,380	0	122	175	1,083	0	12,427	0	1,178	1,239	10,010	0	
Other/unknown	14,299	13	901	2,419	10,955	11	131,644	102	9,205	19,164	103,099	74	
Use of Nursing Facilities <sup>c</sup>													
Entire year	85	18	67	0	0	0	757	143	614	0	0	0	
Part year	93	4	88	1	0	0	789	42	735	12	0	0	
None	70,509	51	4,912	12,993	52,401	152	627,826	324	50,776	94,603	480,833	1,290	
Maintenance Assistance Statu	ıs												
Cash	16,437	23	3,831	5,876	6,707	0	148,574	214	39,788	44,265	64,307	0	
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0	
Poverty related	37,274	0	0	3,520	33,602	152	335,838	0	0	20,738	313,810	1,290	
Other/unknown	16,976	50	1,236	3,598	12,092	0	144,960	295	12,337	29,612	102,716	0	
Managed Care (MC) Status													
Fee-for-service (FFS) all year	70,687	73	5,067	12,994	52,401	152	629,372	509	52,125	94,615	480,833	1,290	
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

#### APPENDIX TABLE A.2

#### MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup> NONDUAL BENEFICIARIES, WYOMING, 2005

#### Beneficiaries and Benefit Months in Cell J of Table 1 Included in Cell K of Table 1 Excluded from Cell K of Table 1 Number of Number of Number of Number of Number of Number of Beneficiaries Benefit Months Beneficiaries Benefit Months Beneficiaries Benefit Months ΑII 70,687 629,372 70,687 629,372 0 0 Fee-for-service (FFS) all year 70,687 629,372 70,687 629,372 0 0 FFS part year, with Rx claims 0 0 0 0 0 0 FFS part year, with no Rx claims 0 0 0 0 0 0 Managed care (MC) all year, with Rx claims 0 0 0 0 0 0 0 0 0 0 0 MC all year, with no Rx claims 0

Source: Data for this table are from the MAX 2005 file for Wyoming, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.